title: Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis.
abstract: The case history is presented of a patient with cystic fibrosis in whom the treatment of allergic bronchopulmonary aspergillosis with itraconazole produced an initial response but was complicated by profound adrenal shutdown and impairment of inhaled steroid clearance resulting in paradoxical Cushing's syndrome. The authors conclude that, while it is laudable to attempt to reduce the steroid burden in any patient, it is imperative that due vigilance is exercised when using a combination of agents which interact. If such a combination therapy is embarked upon, regular assessment of the pituitary adrenal axis is advisable.
authors.affiliation: Adult CF Unit Papworth Hospital, Papworth NHS Trust, Papworth Everard, Cambridge CB3 8RE, UK. jsp35@hermes.cam.ac.uk
authors.forename: J S
authors.initials: JS
authors.lastname: Parmar
authors.forename: T
authors.initials: T
authors.lastname: Howell
authors.forename: J
authors.initials: J
authors.lastname: Kelly
authors.forename: D
authors.initials: D
authors.lastname: Bilton
mesh_terms: D000328:Adult; D000730:Androstadienes / Q000009:adverse effects*; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000935:Antifungal Agents / Q000627:therapeutic use*; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000188:drug therapy*; D003480:Cushing Syndrome / Q000139:chemically induced*; D004347:Drug Interactions; D000068298:Fluticasone; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use*; D008297:Male
chemical_list: D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D000935:Antifungal Agents; D017964:Itraconazole; D000068298:Fluticasone